Direct electrical quantification of glucose and asparagine from bodily fluids using nanopores by Galenkamp, Nicole Stéphanie et al.
  
 University of Groningen
Direct electrical quantification of glucose and asparagine from bodily fluids using nanopores






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Galenkamp, N. S., Soskine, M., Hermans, J., Wloka, C., & Maglia, G. (2018). Direct electrical quantification
of glucose and asparagine from bodily fluids using nanopores. Nature Communications, 9(1), [4085].
https://doi.org/10.1038/s41467-018-06534-1
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
ARTICLE
Direct electrical quantiﬁcation of glucose and
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Crucial steps in the miniaturisation of biosensors are the conversion of a biological signal into
an electrical current as well as the direct sampling of bodily ﬂuids. Here we show that protein
sensors in combination with a nanopore, acting as an electrical transducer, can accurately
quantify metabolites in real time directly from nanoliter amounts of blood and other bodily
ﬂuids. Incorporation of the nanopore into portable electronic devices will allow developing
sensitive, continuous, and non-invasive sensors for metabolites for point-of-care and home
diagnostics.
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The ability to monitor the health of individuals thatexchange information through the Internet withoutrequiring human intervention would undoubtedly bring
about a revolution in personalised healthcare. Over the past
decades, the miniaturisation of electronic devices combined with
recent advances in the wireless transmission of data and micro-
ﬂuidics have opened up new possibilities for making such devices.
However, one key area that is preventing their breakthrough is
the production of sensing elements for biologically relevant
molecules, which can be easily interfaced with silicon-based
electronics. Such elements have long lagged behind the electronic
industry in terms of miniaturisation and cost reduction.
At the moment, biosensors that can be integrated in electronic
devices rely mostly on the electric signal that is generated by the
oxidation of a target analyte catalysed by an immobilised
enzyme1. However, such oxidase enzymes are not ubiquitous, and
today’s commercially available home diagnostic and implantable
devices are entirely limited to one well-known example: the
glucose sensor. However, despite the sensor has seen many
improvements since it was ﬁrst introduced in the early 1960s2, it
still suffers from limitations including enzyme instability, com-
plicated surface immobilisation procedures, baseline shifts, and
does not tolerate well changes in micro-environmental factors
such as changes in pH and ionic strength3–5.
Nanopores, which are nanometre-sized water conduits span-
ning biological or artiﬁcial membranes, are emerging as a new
class of biosensors. When a potential is applied, the ﬂux of ions
across an individual nanopore generates an electrical signal that
allows direct interfacing with electronic devices. Most notably,
nanopores can be integrated into electronic devices and are now
used for low-cost, high-speed, and portable sequencing of DNA6.
Nanopores can also detect polypeptide7,8 biomarkers. However,
their use in diagnostic devices is complicated by the low, typically
picomolar, concentration of such biomarkers in biological ﬂuids.
By contrast, metabolites are highly abundant in bodily ﬂuids,
and their variation in concentration is linked to many diseases9.
Nanopores equipped with cyclodextrins10, cucurbiturils11, or
cyclic peptides12 may recognise metabolites. However, the
detection and quantiﬁcation of such analytes directly from a
biological sample cannot be easily implemented because the
recognition elements lack selectivity.
Recently, we have shown that the biological nanopore cytolysin
A (ClyA) can be used to monitor the function of proteins when
they are lodged inside the nanopore (Fig. 1a)13–16. Here, using
proteins from a protein family that in cells recognise an enor-
mous variety of molecules, we show that ClyA nanopores can
report the concentration of glucose and asparagine directly from
samples of blood, sweat, and other bodily ﬂuids. Conveniently, no
sample preparation is required and the concentration of the
metabolite can be monitored continuously.
Results
Characterisation of the glucose-binding protein. In this work,
we used a glucose-binding protein (GBP) that binds glucose with
high afﬁnity and speciﬁcity17. GBP belongs to the class of
substrate-binding proteins which, with minor structural differ-
ences, recognise hundreds of different metabolites in cells18. The
structure of the GBP has been solved in the ligand-free state
(open or apo form) conﬁguration and in the closed, ligand-
bound, conﬁguration. Interestingly, NMR studies revealed that in
solution, apo-GBP adopts both conﬁgurations even in the absence
of glucose19. In our experimental setup, GBP (44 nM) was added
to the cis side of a ClyA-AS20 nanopore (hereafter ClyA, Fig. 1a).
A −90 mV voltage bias was then applied across the membrane,
which generates an electro-osmotic ﬂow across the nanopore
promoting the entry of GBP inside ClyA, as observed by an ionic
current blockade (Fig. 1a). Under these conditions, proteins
remained trapped inside the nanopore for an average time of 10.1
± 1.7 s (−90 mV, n= 308 events, N= 3 independent nanopore
experiments). Two current levels (L1, Ires%= 69.1 ± 0.2%, and L2,
Ires%= 67.7 ± 0.3%, with Ires% indicating the percentage ratio
between the open pore current and the blocked pore current,
N= 5, Fig. 1b) could be observed within the ionic current
blockade of GBP. The relative time spent by the protein on L1
(28%) and L2 (72%) corresponded well to the percentage of
closed and open conﬁguration measured for apo-GBP by NMR
spectroscopy (32 and 68%, respectively)19.
Addition of glucose to the trans side of the nanopore increased
the number of events corresponding to the closed conﬁguration
(L1, Fig. 1b, c), while the duration of the events remained nearly
constant (Fig. 1c). As expected for a binding process, the
frequency of blockades scaled linearly with the concentration of
the ligand (Fig. 1c). The ligand-induced closing (kclosing= 6.7 ±
0.3 × 106 s−1 M−1) and opening (kopening= 0.75 ± 0.12 s−1,
500 nM glucose) rate constants could be determined from the
inverse of L1 and L2 dwell times (Fig. 1c), respectively, and were
similar to the values measured by stopped ﬂow (kclosing= 3–4 ×
107 s−1 M−1 and kopening= 1.4 s−1)21. The dependence of the
fractional time of GBP in the closed conﬁguration with the
glucose concentration ﬁtted well to a Hill function with the Hill
coefﬁcient set to one (Supplementary Fig. 1a), from which a
normalised calibration curve could be obtained (Fig. 1c). The
extrapolated apparent binding constant (2.3 ± 0.1 × 10−7 M)
corresponded well to the value measured in bulk (2–5 × 10−7
M)21–23. A GBP variant (GBP-A213R) with reduced afﬁnity for
glucose24,25 showed only one single level in the absence of
glucose (Ires%= 67.7 ± 0.1%, kclosing= 4.69 ± 0.42 × 106 s−1 M−1
and kopening= 121.0 ± 6.9 s−1, Supplementary Fig. 2), correspond-
ing to the open conﬁguration of GBP. GBP-A213R closed at
higher concentrations of glucose (20 µM, Supplementary Fig. 2).
Together, these results indicate that nanopore currents can report
the binding of glucose to GBP, and that the concentration of
glucose inside the nanopore is similar to the concentration
of glucose in bulk.
Quantiﬁcation of glucose from human biological ﬂuids. Next,
we measured the concentration of glucose directly from a panel of
biological samples. Aliquots of blood (10 nL), sweat (2 µL), urine
(200 nL), and saliva (8 µL) were added to the trans chamber of an
electrophysiology setup containing a single ClyA nanopore. The
untreated samples did not alter the stability of the lipid bilayer
over the experimental timescale (up to 100 min, Supplementary
Fig. 3). Large molecules could not enter the narrow trans side of
the nanopore, while small molecule such as glucose could freely
diffuse and bind to the trapped GBP previously added to the cis
chamber (44 nM). Extrapolation from the calibration curve
(Fig. 1c) allowed measuring the concentration of glucose directly
from the diluted biological samples. Comparison with values
measured with existing commercial glucose test kits showed that
the nanopore accurately measured the concentration of glucose in
those biological samples (Table 1 and Supplementary Table 1).
Detection of asparagine. One of the advantages of the nanopore
technique is that single molecules are detected, which in turn
allows the measurement of multiple analytes. To explore this
concept, we used SBD1, a substrate-binding domain analogous to
GBP that recognises asparagine rather than glucose. Asparagine is
a marker for brain damage in acute stroke26, while its abnormal
concentration in blood has been associated to Parkinson’s dis-
ease27. Under −90 mV, the blocked pore level of apo-SBD1
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contained one main current level corresponding to the open
protein conﬁguration (Fig. 2a). The addition of asparagine to the
trans side of the nanopore led to the appearance of an additional
current level corresponding to the closed conﬁguration of SBD1
(Fig. 2a), from which binding constants could be measured
(Fig. 2b, koff= 8.6 ± 0.1 s−1, kon= 1.8 ± 0.1 × 107 M−1 s−1, Kdapp
= 0.50 ± 0.04 μM). As observed before for GBP, the binding
constants measured by the nanopore were similar to the ones
measured in bulk16,28. The percentage of bound fraction was used
to extrapolate the concentration of asparagine in the trans solu-
tion (Fig. 2c). Comparison with an established technique, high
performance liquid chromatography (HPLC) coupled with
ﬂuorescence detection indicated that the nanopore approach can
accurately quantify the concentration of asparagine in all biolo-
gical samples (Table 1, Supplementary Fig. 4, and Supplementary
Table 1). Measurements of asparagine in the presence of high
concentration of glucose, glutamine, and glycine (Supplementary
Fig. 5) conﬁrmed that SBD1 shows no appreciable off-target
binding activity. Measurements of asparagine in urine
with known increasing amounts of asparagine (standard addi-





























































Fig. 1 Nanopore glucose sensor for biological samples. a Cut-through of a surface depiction of a ClyA nanopore (grey) inserted into a lipid bilayer (yellow)
containing a glucose-binding protein (GBP) created with the VMD software. GBP residues are coloured by the software according to their type. On the
right are cartoon representations of GBP proteins in the open, ligand-free state and closed, liganded state. Right from the cartoon is a typical output signal
(current trace) showing the entry of GBP proteins inside the nanopore. IB is the blocked pore current signal and IO the open pore current signal. b Effect of
increasing concentrations of glucose added to the trans solution to the signal induced by GBP proteins internalised into a ClyA nanopore at −90mV. On
the left are shown current traces, on the right all-point histograms of ~50 s of a current trace. c Dependency of the opening and closing rates, measured as
the inverse of dwell times (top) and the fraction of the closed state (bottom) on the concentration of glucose in the trans solution. The lines in the top graph
are linear ﬁts and the line in the graph below indicates the ﬁtting to a Hill function. The solution used for the electrical recordings contained 150mM NaCl
and 15 mM Tris-HCl set at pH 7.5. Current traces were collected applying a Bessel low-pass ﬁlter with a 2 kHz cutoff and sampled at 10 kHz at room
temperature (25 °C). A post-acquisition Gaussian ﬁlter of 200Hz was applied. Error bars represent the standard deviation between independent
experiments (N= 3)
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Simultaneous detection of glucose and asparagine in sweat. The
residual current of the open conﬁguration of SBD1 (Ires%= 67.3
± 0.3%) was markedly different than the open protein conﬁg-
uration of GBP (Ires%= 69.1 ± 0.2%). Thus, when GBP (44 nM)
and SBD1 (120 nM) were simultaneously present in the cis
solution, blockades corresponding to each protein adaptor could
be readily distinguished (Fig. 3), allowing the simultaneous
detection of glucose and asparagine from a sweat sample (Fig. 3).
Discussion
Portable devices for home diagnostics are sought after because
they would reduce the cost of care and increase life expectancy by
detecting diseases at an early stage. Here we showed that ClyA
nanopores equipped with internal protein adapters can accurately
measure the concentration of small metabolites by directly sam-
pling tiny volumes of biological samples with no sample pre-
paration. Such protein adapters are ideal biosensors, because they
evolved over billion years to recognise biologically relevant
molecules with high selectivity and sensitivity. Integration of
ClyA nanopores with a panel of protein adapters in existing
commercial portable devices would provide an off-the-shelf low-
cost device for home diagnostics. The single-molecule nature of
the sensor provides advantages over ensemble technologies,














































Fig. 2 Binding constants for asparagine binding to SBD1. a Current traces and all-point current histograms showing the binding of asparagine to SBD1 (120
nM, cis) inside a ClyA nanopore. Asparagine was added to the trans solution and the voltage was set to −90mV. b Dependency of the opening and closing
rates (calculated from the inverse of the dwell times) on the concentration of asparagine in the trans solution. The black and blue lines are linear ﬁts.
c Dependency of the percentage of the closed conﬁguration on the concentration of asparagine in the trans solution. The blue line indicates ﬁtting to a Hill
function with the Hill coefﬁcient set to one. The solution used for the electrical recording contained 150mM NaCl, 15 mM Tris-HCl, pH 7.5. Current traces
were collected applying a Bessel low-pass ﬁlter with a 2 kHz cutoff and sampled at 10 kHz at room temperature (25 °C). A post-acquisition Gaussian ﬁlter
of 200Hz was applied. Error bars represent the standard deviation between independent experiments (N= 3)
Table 1 Comparison of different methods measuring the concentrations of glucose and asparagine in different biological samples
Glucose Asparagine
Nanopore Sampled volume Commercial assay Nanopore Sampled volume LC assay
Sweat 105 ± 9 µM 2 µL 105 ± 7 µM 94.6 ± 5.0 µM 5 µL 90.9 ± 4.1 µM
Urine 368 ± 7.5 µM 200 nL 381 ± 6 µM 35.4 ± 2.8 µM 4 µL 89.7 ± 3.6 µM
Saliva 5.71 ± 0.48 µM 15 µL 10.4 ± 7.9 µM 1.36 ± 0.22 µM 30 µL ND
Blood sample 1 5.09 ± 0.88mM 10 nL 5.3 mM 10.2 ± 0.2 µMa 5–15 µL 6.7 ± 0.2 µMa
Blood sample 2 4.91 mM 10 nL 4.9 mM
Blood sample 3 4.21 mM 10 nL 4.4mM
The concentration of glucose was measured using a glucose (HK) assay kit (Sigma-Aldrich) except for blood samples, where an Accu-Chek® Aviva (Roche) system was used. Since the latter system did
not provide an error in the measurement, three different blood samples were tested. The concentration of asparagine was measured using a HPLC assay coupled with ﬂuorescence detection. Sweat and
urine were directly sampled, while the proteins in saliva and serum were precipitated with 8% trichloroaceticacid prior the HPLC measurements. The concentration of asparagine in saliva was too low to
be measured with the HPLC assay
aSince a pre-puriﬁcation step was required for LC sampling, serum instead of blood was used for the quantiﬁcation of asparagine. Error is SD
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simultaneously without the need of calibration for signal drift.
Thus, nanopores equipped with internal protein adapters are
ideal next-generation biosensors for miniaturised, non-invasive
diagnostic, and wearable devices.
Methods
Chemicals, DNA, enzymes, and lipids. Unless otherwise speciﬁed all chemicals
were bought from Sigma-Aldrich. DNA was purchased from Integrated DNA
Technologies (IDT), enzymes from Thermo Fisher Scientiﬁc, and lipids from
Avanti Polar Lipids.
GBP cloning. To allow cloning, a NcoI site (CCATGG) was introduced into the
sequence of the wild-type GBP from Escherichia coli at the beginning of the gene
(5′-end, beginning of the leader peptide). To maintain the open-reading frame, two
extra bases were inserted after the NcoI site, resulting in an additional alanine
residue after the starting methionine. For puriﬁcation, a His6-tag was attached at
the C-terminus of GBP, via a ﬂexible glycine–serine–serine linker and the open-
reading frame was terminated by two consecutive stop codons, followed by a Hind
III restriction site (3′-end). The attachment of the His6-tag was carried out in two
consecutive PCR reactions. During the ﬁrst PCR reaction, the GBP gene was
ampliﬁed directly from a single BL21 (DE3) E. coli (Lucigen) colony using Phire
Hot Start II DNA polymerase, 0.4 µM dNTPs, 6 µM of MS-Glu_F (TATATATC
CATGGCTaataagaaggtgataaccctgtctgctgtg), and MS-Glu_r1 (gatggtgatgGCTGCT
GCCtttcttgctgaattcagccaggttgtctttatctacgcc) primers in a 50 µL reaction volume.
The PCR reaction cycling protocol was as follows: pre-incubation step at 98 °C for
30 s and then 30 cycles of denaturation at 98 °C for 5 s and extension at 72 °C for 1
min. The ampliﬁed product was puriﬁed using QIAquick PCR Puriﬁcation Kit
(Qiagen) and served as a template for the second PCR reaction, which used ~100
ng of the puriﬁed PCR product ampliﬁed by Phire Hot Start II DNA polymerase
using 0.4 µM dNTPs, 6 µM of MS-Glu_F, and MS-Glu_r2 (atatata-
taagctttcattaatggtGATGGTGATGGCTGCTGCCTTTCTTGCTGAATTC) primers
in 300 µL volume. The cycling protocol was the same as in the previous step. The
resulting PCR product encoding for the His6-tagged GBP gene was puriﬁed with
QIAquick PCR Puriﬁcation Kit (Qiagen) and digested with NcoI and HindIII
(FastDigest, Fermentas). The gel puriﬁed insert (QIAquick Gel Extraction Kit,
Qiagen) was cloned under control of the T7 promoter into the pT7-SC1 expression
plasmid29 using sticky-end ligation (T4 ligase, Fermentas) via NcoI (5′) and
HindIII (3′) sites. Ligation mixture of 0.6 µL was transformed into 50 µL of E.
cloni® 10G cells (Lucigen) by electroporation. The transformed bacteria were
grown overnight at 37 °C on ampicillin-containing (100 µg/mL) LB agar plates. The
identity of the clones was conﬁrmed by sequencing.































Construction GBP-A213R mutant. The GBP-A213R was constructed using the
QuickChange protocol for site-directed mutagenesis30 on a circular plasmid tem-
plate DNA (pT7-SC1 containing GBP gene) with Phire® Hot Start Polymerase
(Finnzymes) by using two complementary primers. Six µM forward
(GGTTATCGCCAACAACGATAGGATGGCA) and 6 µM reverse primer
(GCGCCCATTGCCATCCTATCGTTGTT) containing a codon encoding the
mutation were used in 50 µL ﬁnal volume to amplify the gene (pre-incubation at
98 °C for 30 s, then 30 cycles of: denaturation at 98 °C for 5 s, extension at 72 °C for
1.5 min). The PCR product was incubated with DpnI (1 FDU) for 1 h at 37 °C to
digest the plasmid template. The remaining DpnI enzyme was deactivated at 55 °C.
The mixture was then incorporated into E. cloni® 10G cells (Lucigen) by electro-
poration. Transformants containing the plasmid were grown overnight at 37 °C on
LB agar plates supplemented with 100 μg/mL ampicillin and 1% glucose. Single
colonies were picked and inoculated into 10 mL LB medium supplemented with
100 mg/L of ampicillin for plasmid DNA preparation. The presence of the muta-
tion was conﬁrmed by sequencing of the plasmid.
Puriﬁcation of SBD1. Substrate-binding domains carrying a histidine-tag were
expressed in E. coli strain MC1061 and puriﬁed as described previously.28 The cell
lysate was mixed with 50 mM potassium phosphate, pH 8.0, 200 mM KCl, 20%
glycerol (buffer A) supplied with 20 mM imidazole and incubated with Ni2
+-sepharose (GE Healthcare) resin for 1 h at 4 °C. Next, the resin was washed with
20 column volumes of buffer A supplied with 50 mM imidazole, followed by
protein elution with 500 mM imidazole in buffer A. To prevent protein aggrega-
tion, 5 mM EDTA was added immediately after elution. Afterwards the histidine-
tag was cleaved off by adding 2.5% w/w His-TEV (S219V)31 and dialyzing over-
night against 50 mM Tris-Cl, 0.5 mM DTT, 0.5 mM EDTA, pH 8.0 to remove
imidazole. The histidine-tagged tobacco etch virus (TEV) protease and residual
uncut protein were removed by loading it on a small 0.5 mL Ni2+-sepharose col-
umn collecting the ﬂow-through. Next, proteins were further puriﬁed with size-
exclusion chromatography on a Superdex-200 column (GE Healthcare) equili-
brated with 50 mM Tris-HCl, 200 mM NaCl, pH 7.5. Peak fractions were collected
in aliquots and were stored at −80 °C after ﬂash-freezing in liquid nitrogen.
Puriﬁcation of ClyA-AS. E. cloni® EXPRESS BL21 (DE3) cells were transformed
with the pT7-SC1 plasmid containing the ClyA-AS gene. ClyA-AS contains eight
mutations relative to the S. Typhi ClyA-WT: C87A, L99Q, E103G, F166Y, I203V,
C285S, K294R, and H307Y. Transformants were selected after overnight growth at
37 °C on LB agar plates supplemented with 100 mg/L ampicillin and 1% glucose.
The resulting colonies were inoculated into 400 mL 2xYT medium containing 100
mg/L of ampicillin. The cells were grown at 37 °C (200 r.p.m. shaking) until an
OD600 of ~0.8 was reached. The expression of ClyA-AS was induced by addition of









Fig. 3 Multiplexed detection of glucose and asparagine from sweat.
Schematic representation (above) and current blockades with its all-point
current histogram (below) of two consecutive events showing the entry of
SBD1 and GBP into a ClyA nanopore, respectively, under −90mV applied
transmembrane potential. The trans solution contained 5 µL of sweat
constituting a 100-fold dilution. The solution used for the electrical
recordings contained 150mM NaCl and 15 mM Tris-HCl set to pH 7.5.
Current traces were collected applying a Bessel low-pass ﬁlter with a 2 kHz
cutoff and sampled at 10 kHz at room temperature (25 °C). A post-
acquisition Gaussian ﬁlter of 200 Hz was applied
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day, the bacteria were harvested by centrifugation at 6000×g at 4 °C for 25 min and
the pellets were stored at −80 °C. The pellets containing monomeric ClyA-AS were
thawed and solubilized with 20 mL lysis buffer (150 mM NaCl, 15 mM Tris-HCl,
pH 7.5, 1 mM MgCl2, 0.2 units per mL DNaseI, 10 mM imidazole, 10 µg/mL
lysozyme) and incubated for 20 min at 37 °C. The bacteria were then lysed by
sonication (Branson). The lysate was subsequently centrifuged at 6000×g at 4 °C for
20 min and the cellular debris discarded. The supernatant was mixed with 150 μL
of Ni-NTA resin (Qiagen) in wash buffer (10 mM imidazole, 150 mM NaCl, 15
mM Tris-HCl, pH 7.5). After 1 h, the resin was loaded into a column (Micro Bio
Spin, Bio-Rad) and washed with ~5 mL of the wash buffer. The protein was eluted
with ~100 μL elution buffer (300 mM imidazole, 150 mM NaCl, 15 mM Tris-HCl,
pH 7.5). Type I ClyA-AS oligomers were obtained by incubation of ClyA-AS
monomers with 0.2% β-dodecylmaltoside (DDM) for 30 min at 37 °C. The oligo-
mers were separated from monomers by blue native polyacrylamide gel electro-
phoresis (BN-PAGE, Bio-Rad) using 4–20% polyacrylamide gels20. The band
corresponding to type I ClyA-AS were cut out from the gel and was extracted in
150 mM NaCl, 15 mM Tris-HCl, pH 7.5 supplemented with 0.2% DDM and 10
mM EDTA.
Puriﬁcation of GBP. E. cloni® EXPRESS BL21 (DE3) cells were transformed with
the pT7-SC1 plasmid containing the His6-tagged GBP gene. Transformants were
selected after overnight growth at 37 °C on LB agar plates supplemented with 100
mg/L ampicillin and 1% glucose. The resulting colonies were inoculated into 400
mL 2xYT medium containing 100 mg/L of ampicillin. The cells were grown at 37 °
C (200 r.p.m. shaking) until an OD600 of ~0.8 was reached. The expression of GBP
was induced by addition of 0.5 mM IPTG. The cell cultures were further grown
overnight at 25 °C. The next day, the bacteria were harvested by centrifugation at
6000×g at 4 °C for 25 min. The protein was puriﬁed directly afterwards by osmotic
shock. The pellets were thoroughly dissolved in 20% ice-cold sucrose solution and
incubated, while shaking at 4 °C for 10 min. The cell suspension was centrifuged at
6000×g at 4 °C for 10 min and cells collected. The cells were re-suspended in 4×
volume of ice-cold MilliQ water supplemented with 5 mM MgCl2 and incubated,
while shaking, on ice for 20 min. The cells collected again by centrifugation at
6000×g at 4 °C for 20 min. The supernatant was mixed with 150 μL of Ni-NTA
resin (Qiagen) in wash buffer (10 mM imidazole, 150 mM NaCl, 15 mM Tris-HCl,
pH 7.5). After 1 h, the resin was loaded into a column (Micro Bio Spin, Bio-Rad)
and washed with ~5 mL of the wash buffer. The protein was eluted with ~500 μL
elution buffer (300 mM imidazole, 150 mM NaCl, 15 mM Tris-HCl, pH 7.5). The
protein (500 μL) was then dialysed exhaustively overnight against dialysis buffer
(total volume of 1500 mL; 5 mM EDTA,150 mM NaCl, 15 mM Tris-HCl, pH 7.5),
whereby the dialysis buffer was replaced for fresh buffer at least three times. Protein
concentration was measured by using the Nanodrop 2000C at 280 nm (Thermo
Fisher Scientiﬁc). Protein was stored with 10% glycerol in −80 °C after ﬂash-
freezing until further use.
Electrical recordings in planar lipid bilayers. The setup consisted of two
chambers separated by a 25 μm thick polytetraﬂuoroethylene ﬁlm (Goodfellow
Cambridge Limited) containing an aperture of approximately 100 μm in diameter.
The aperture was pre-treated with a solution of hexadecane [10% (v/v) in pentane]
to leave a hydrophobic coating to support bilayer formation. 1,2-diphytanoyl-sn-
glycero-3-phosphocholine (DPhPC) in pentane (10 mg/mL) was then added to the
buffer (500 µL, 150 mM NaCl, 15 mM Tris-HCl, pH 7.5) present in both com-
partments. After evaporation of the pentane, a lipid monolayer at the air–water
interface can self-assemble spontaneously by lowering and raising the buffer across
the aperture. 0.01–0.1 ng of puriﬁed ClyA-AS were added to the grounded cis
compartment. The reconstitution of single nanopores was monitored electrically by
applying a −35 mV bias. ClyA-AS nanopores display a higher open pore current at
positive than at negative applied potentials, which provides a useful tool to
determine the orientation of the pore. After insertion of a single pore, GBP or
SBD1 were added to the cis compartment. This was followed by addition of a
glucose or asparagine sample or bodily ﬂuid sample in the trans compartment.
Data recordings and analysis. All traces were routinely recorded at −90 mV or
−60 mV applied transmembrane potential by using an Axopatch 200B patch clamp
ampliﬁer (Axon Instruments) and digitised with a DigiData 1440 A/D converter
(Axon Instruments). The data was sampled by applying a 2 kHz low-pass Bessel
ﬁlter and at a frequency of 10 kHz. Obtained traces were ﬁltered digitally with a
Gaussian low-pass ﬁlter with a 100 Hz cutoff. Data were recorded by using the
Clampex 10.4 software (Molecular Devices) and the subsequent analysis was car-
ried out with the Clampﬁt software (Molecular Devices).
Analysis of current traces. Current transitions between the open and closed levels
were analysed using the “single-channel search” function using Clampﬁt software
(Molecular Devices). Events shorter than 2 ms were ignored. The mean dwell times
for the ligand-induced closing (τon) and ligand-independent opening (τoff) of GBP
were obtained from single exponential ﬁts to histograms of the inter-event times
and dwell times, respectively. The mean lifetime of the open state (τon) was
converted to the on-rate constants by using kon= 1/τon[glucose], where [glucose] is
the concentration of glucose added to the trans side. The τoff was converted to the
off-rate by using koff= 1/τoff. The equilibrium binding constant was calculated by
plotting the fraction of closed conﬁguration against the concentration of substrate
and the data ﬁtted to a Hill function (Fig. 1c). The Kdapp is the concentration of
substrate at 50% signal saturation.
Calibration curve for GBP binding to glucose. Values of the relative open/closed
population were obtained from Gaussian ﬁttings to all-point current histograms
(Fig. 1b). In a typical experiment, an all-point histogram was created from indi-
vidual current blockade longer than ~5 s. Gaussian ﬁttings were then used to
measure the area under the curve corresponding to the open and closed conﬁg-
uration for each protein blockade. Then, all areas were added together to calculate
the overall percentage of open and closed conﬁguration. Since the open and closed
conﬁgurations were still observed in the absence of glucose or at saturated con-
centration of glucose (e.g., 50 µM, Supplementary Fig. 1b), the open/closed





where xnorm is the normalised value, xmin is the fraction of the apo-protein in the
closed conﬁguration measured during each experiment before addition of glucose,
and 0.94 is the fraction of closed conﬁguration at saturating glucose concentrations.
The fraction of closed conﬁguration was then plotted against the concentration of
substrate and the data ﬁtted to a Hill function (Fig. 1c). This graph was used as a
calibration curve to determine the ligand concentration in the bodily ﬂuids.
Commercial glucose tests. A glucose assay kit (HK) from Sigma-Aldrich and a
commercial glucose metre (Accu-chek® Performa, Roche, Switzerland) were used
to determine the glucose in the bodily ﬂuids. The solution of the glucose assay kit
contains a hexokinase enzyme that uses adenosine triphosphate (ATP) as a co-
factor to phosphorylate glucose. The glucose-6-phosphate (G6P) is then oxidised to
6-phospho-gluconate in the presence of oxidised nicotinamide adenine dinucleo-
tide (NAD) in a reaction catalysed by glucose-6-phosphate dehydrogenase (G6PD).
The generation of NADH was spectrophotometrically observed by measuring
absorbance at 340 nm. Under these conditions, the ﬁnal concentration of produced
NADH corresponds to the glucose concentration in the sample. In order to per-
form the experiment, a dilution of bodily ﬂuid was added to the reaction mixture.
The reaction was incubated for 15 min at room temperature and then the absor-
bance was measured at 340 nm (ε= 6220M−1 cm−1). For each sample, three
different dilutions were measured. The commercial glucose metre Accu-Chek® uses
a mutant variant of quinoprotein glucose dehydrogenase and has a measurement
range between 0.6 and 33.3 mmol/L32. The Accu-Chek® is considered to be a
reliable device for monitoring glucose levels in blood from ﬁnger pricks33.
Sample collection. The bodily ﬂuids were collected from two healthy volunteers
who were fasting for at least 1 h (woman in her 20’s and men in his 30’s). The
blood samples were collected shortly before the experiments to minimise ex vivo
artefactual changes. Sweat, urine, and saliva samples were either freshly collected
before, or stored at −20 °C, before the start of experiments. The solutions were kept
on ice for the duration of an experiment. The blood samples were diluted 500-folds
and the urine sample 10-folds with buffer (150 mM NaCl, 15 mM Tris-HCl, pH
7.5) before adding 5 and 2 µL, respectively, to the trans compartment.
Measurement time. The concentration of analytes in blood was measured by
calculating the relative fraction of the open vs. closed conﬁguration from Gaussian
ﬁttings to all-point current histograms over a certain integration time (Fig. 1b). For
asparagine, the integration time was ~30 s, and for glucose ~10 min. We tested
smaller integration times (Supplementary Fig. 7) and found that at least 5 min are
necessary to obtain accurate measurements for glucose and about 10 s for aspar-
agine. The difference between the two analyte lies in the different afﬁnities of the
proteins for their ligands. Glucose binds relatively strongly to GBP (kopening= 0.75
± 0.12 s−1, 500 nM glucose), compared to the binding of asparagine to SBD1
(kopening= 8.6 ± 0.1 s−1, 800 nM asparagine), thus longer integration times are
required for accurate reading. It follows that (GBP-A213R), which shows reduced
afﬁnity for glucose (kopening= 121.0 ± 6.9 s−1 at 20 µM glucose, Supplementary
Fig. 2), will provide faster reading times, with lower sensitivity, but wider detection
range.
Bilayer stability. All measurements were made by adding small volumes of bio-
logical samples to an electrophysiology chamber (500 µL). We did not observe a
particular instability of the bilayer (Supplementary Figs. 3 and 4), except when
lower than 1:50 or 1:30 dilutions of serum or saliva were used (Supplementary
Fig. 4). Typically, with a 1:33 dilution of serum the lipid bilayer was stable for 9.4 ±
9.2 min (the error is SD, N= 10).
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Measurement of asparagine using high performance liquid chromatography
(HPLC). Urine and sweat samples were analysed without any pretreatment directly
after the addition of 50 µL standard additions to 50 µL sample while phosphate
buffered saline was used as a blank.
Proteins in 150 µL saliva and 60 µL serum samples were precipitated by
incubation with 8% trichloroaceticacid (CASnr 76–03–9) for 5 min at 60 °C and
450 r.p.m. using a thermomixer (comfort, Eppendorf, Hamburg, Germany)
followed by cooling on ice for 30 min and centrifugation for 10 min at 20,000×g
and 4 °C. A ﬁxed volume of the supernatant was taken out using a pipette not
taking any precipitate and neutralised with a four times larger volume of saturated
sodium borate (CASnr 1303–96–4). After mixing, a concentrator (SpeedVac 5301,
Eppendorf, Hamburg, Germany) was used to evaporate all liquids by vacuum
evaporation at 60 °C and 240×g, and the sample was reconstituted in an identical
volume of water as the former ﬁxed amount of supernatant. A ﬁnal 5-min-long
centrifugation at 20,000×g step was performed and the supernatant was stored at
4 °C before analysis.
HPLC quantiﬁcation of asparagine was performed on an Agilent 1100 HPLC
binary system (Agilent, Santa Clara, USA) equipped with an 1100 Fluorescence
detector (FLD) and a Gemini C18 column (2 × 250 mm, 5 µm, Phenomenex,
Torrance, USA) while a 40 mM sodium phosphate buffer, pH 7.8 (solvent A) and a
mixture of 45:45:10 acetonitrile/methanol/water (solvent B) were used. The
ﬂuorogenic labelling of amino acids was performed automatically by the auto
sampler of the HPLC machine using a mixture of 10 mg o-phtalaldehyde (OPA,
CASnr 643-79-8) and 10 µL 3-mercaptapropionic acid (3MPA, CASnr 107-96-0) in
water as reagent. The auto sampler mixed 0.5 µL sample with 1.3 µL 0.4 N borate
buffer, pH 10.2 followed by 0.5 µL reagent and 7.6 µL water right before each
injection. After the sample injection, amino acids were separated by applying
solvent B at 1.5%/min increase for 25 min using a ﬂow rate of 250 µL/min (the
initial solvent B concentration was 5%). Thereafter, the column was cleaned for 5
min at 66% solvent B followed by another 12 min at 100% solvent B. Then the
column was equilibrated back to 5% solvent B. Fluorescence was measured at an
excitation wavelength of 340 nm and an emission wavelength of 450 nm.
Quantiﬁcations were performed using the method of standard addition at three
different concentrations of analyte (10, 50, and 200 µM). The concentration of the
analyte was obtained by measuring the peak areas, while each sample was analysed
in triplicate. Citrulline was added as internal standard at 200 µM to correct for
saliva and serum sample handling volume differences next to control run-to-run
retention time shifts regarding all samples.
Data availability
The datasets generated during and/or analysed during the current study are available
from the corresponding author on reasonable request.
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